

## News Release

September 28, 2016  
Maruho Co., Ltd  
Astellas Pharma Inc.

### Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area

Osaka and Tokyo (Japan), September 28, 2016 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) announce today that they have entered into an exclusive license agreement for a novel, Janus Kinase (JAK) inhibitor developed by Astellas (INN: peficitinib, development code: ASP015K) for treatment in the skin disease area by topical formulation.

Under this agreement, Astellas gives Maruho worldwide, exclusive rights to develop, manufacture and commercialize topical formulation of peficitinib for treatment in the skin disease area. In return, Maruho will pay Astellas an up-front payment at the time of the execution of the agreement and will also pay milestone payments upon the achievement of certain development milestones. Astellas is further entitled to receive royalty payments on net sales of the product developed by Maruho. Maruho will conduct further development, production and commercialization alone and bear all costs associated.

All rights other than those for topical formulations for skin diseases are retained by Astellas.

Astellas continues development of peficitinib in the field of immunology including rheumatoid arthritis.

Maruho and Astellas look forward to contributing to the treatment of skin diseases through the future development of topical formulation of peficitinib by Maruho and providing a new treatment option.

**About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at [www.astellas.com/en](http://www.astellas.com/en).

**About Maruho**

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing, and commercialization of dermatological products. Founded in 1915, Maruho has 1,335 employees (as of the end of September 2015), and net sales were approximately 67.0 billion yen in the previous fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information about Maruho Co., Ltd., please refer to [www.maruho.co.jp/english](http://www.maruho.co.jp/english)

**Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contact Information
Maruho Co., Ltd. Public Relations Department TEL:+81-06-6371-8831 HP: <a href="https://www.maruho.co.jp">https://www.maruho.co.jp</a>
Astellas Pharma Inc Corporate Communications TEL:+81-03-3244-3201 HP: <a href="http://www.astellas.com/jp">http://www.astellas.com/jp</a>